CN113429477B - Preparation method and application of novel coronavirus, milk or serum containing specific antibody and produced by immune dairy cow thereof - Google Patents
Preparation method and application of novel coronavirus, milk or serum containing specific antibody and produced by immune dairy cow thereof Download PDFInfo
- Publication number
- CN113429477B CN113429477B CN202110011295.2A CN202110011295A CN113429477B CN 113429477 B CN113429477 B CN 113429477B CN 202110011295 A CN202110011295 A CN 202110011295A CN 113429477 B CN113429477 B CN 113429477B
- Authority
- CN
- China
- Prior art keywords
- milk
- serum
- novel coronavirus
- virus
- coronavirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 85
- 239000008267 milk Substances 0.000 title claims abstract description 85
- 210000004080 milk Anatomy 0.000 title claims abstract description 85
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 75
- 210000002966 serum Anatomy 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 235000013365 dairy product Nutrition 0.000 title description 4
- 241000700605 Viruses Species 0.000 claims abstract description 50
- 208000001528 Coronaviridae Infections Diseases 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 241001678559 COVID-19 virus Species 0.000 claims abstract 4
- 102100028279 WW domain-binding protein 1 Human genes 0.000 claims description 18
- 101710160563 WW domain-binding protein 1 Proteins 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 230000003053 immunization Effects 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 9
- 239000012071 phase Substances 0.000 claims description 9
- 230000002779 inactivation Effects 0.000 claims description 7
- 230000003472 neutralizing effect Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 3
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims description 3
- 229940063655 aluminum stearate Drugs 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000012795 verification Methods 0.000 claims description 3
- 238000010171 animal model Methods 0.000 claims description 2
- 229940124452 immunizing agent Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 26
- 102000004169 proteins and genes Human genes 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 14
- 210000004072 lung Anatomy 0.000 abstract description 11
- 206010035664 Pneumonia Diseases 0.000 abstract description 8
- 230000002829 reductive effect Effects 0.000 abstract description 7
- 239000013585 weight reducing agent Substances 0.000 abstract description 4
- 230000034994 death Effects 0.000 abstract description 3
- 231100000517 death Toxicity 0.000 abstract description 3
- 230000009545 invasion Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 30
- 239000000243 solution Substances 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 241000283690 Bos taurus Species 0.000 description 17
- 238000000034 method Methods 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 210000003501 vero cell Anatomy 0.000 description 8
- 241000315672 SARS coronavirus Species 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 5
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 5
- 230000003044 adaptive effect Effects 0.000 description 5
- 238000010009 beating Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000007865 diluting Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 210000003437 trachea Anatomy 0.000 description 5
- 210000001944 turbinate Anatomy 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 208000025721 COVID-19 Diseases 0.000 description 3
- 102100031673 Corneodesmosin Human genes 0.000 description 3
- 101710139375 Corneodesmosin Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 229960000380 propiolactone Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000004201 immune sera Anatomy 0.000 description 2
- 229940042743 immune sera Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 102000048657 human ACE2 Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Environmental Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention belongs to the technical field of biology, and discloses a preparation method and application of a novel coronavirus and specific antibody-containing milk or serum produced by an immune cow thereof. A large amount of immune milk and serum can be obtained by utilizing the inactivated novel coronavirus SARS-CoV-2/ZY38-1 to immunize a cow, and both the immune milk and the serum contain high-content antibodies, so that the virus can be effectively neutralized, the virus invasion cells can be prevented, and the SARS-CoV-2 virus resistance effect is obvious; after the Igs protein purified by the immune milk is injected into a mouse, the death rate of the mouse infected by the new coronavirus can be obviously reduced, the influence of the new coronavirus infection on the weight reduction of the mouse is reduced, and the virus content in the lung tissue of the mouse is reduced. The immune milk and the serum provided by the invention can be used as antibody sources of a new coronary pneumonia prevention and treatment preparation, and make up for the limitation of the source of new coronary pneumonia rehabilitation plasma.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to preparation and application of positive milk and serum of severe acute respiratory syndrome coronavirus type 2 and specific antibodies thereof.
Background
A novel coronavirus pneumonia (coronavirus disease 19, COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) appeared at the end of 2019 and presented a global outbreak, seriously endangered human health and public health safety, brought huge burden to world society and economy, and caused high attention globally. By 7 months in 2020, the total number of confirmed cases of new coronary pneumonia exceeds 1400 million and the number of deaths exceeds 60 million. Many foreign and domestic scholars speculate that new coronavirus or similar influenza virus will coexist with human for a long time. Moreover, the existing research reports and data show that the fatality rate of SARS-CoV-2 is much higher than that of influenza, but no therapeutic and prophylactic preparation or vaccine specifically aiming at resisting novel coronavirus can be used so far, so that an effective prevention and treatment method aiming at SARS-CoV-2 is urgently needed to be found. Inhibition of viral entry into cells is a very effective therapeutic strategy. Studies have reported that angiotensin converting enzyme 2 (ACE 2) is a functional receptor for SARS-CoV, and is capable of binding with high efficiency to S protein on the surface of SARS-CoV, which invades cells via the cell surface receptor ACE2 (Li Wenhui et al, 2003; Kuba K, 2005). Therefore, researchers have constructed recombinant ACE2 protein, which was found to have potential therapeutic effects on SARS-CoV (Kuba K, 2005). Daniel W et al (2020) reported that the S protein of SARS-CoV-2 also binds to the ACE2 receptor with much higher affinity than the S protein of SARS-CoV. Vanessa Monteil et al (2020) study reports that when cells are infected with SARS-CoV-2 and incubated with recombinant human ACE2 protein purified in vitro for a period of time, the infectivity of the virus is rapidly reduced, and the reduction range can reach 1000-5000 times, and the study also finds that the infection of S ARS-CoV-2 cannot be inhibited when cells are infected with SARS-CoV-2 and incubated with murine ACE2 protein for a period of time. However, recombinant rACE2 was found to have a half-life of only a few hours and to be cleared quickly in vivo (Wysocki J et al, 2010; Haschke M et al, 2013). Clinically, serum of a rehabilitation patient with the novel coronavirus pneumonia has a certain curative effect on critically ill patients, but a method for treating virus infection by using blood plasma of the rehabilitation patient cannot be popularized, and on one hand, the recovery patient is weak and is not suitable for blood donation, and on the other hand, the recovery patient is limited by factors such as blood plasma sources.
The invention reports that SARS-CoV-2 is put out of fire to immunize milk cow, and the serum and milk after immunization are collected as a special 'antibody' to neutralize SARS-CoV-2 and prevent virus from invading cells for the first time, and the invention is a biological preparation for effective prevention and treatment specially aiming at novel coronavirus infection.
Disclosure of Invention
The invention aims to provide a novel isolated coronavirus, wherein the novel coronavirus strain is delivered to China center for type culture Collection (CGMCC) at 04.01/2021, and is classified and named as follows: SARS-CoV-2/ZY38-1, accession number: CCTCC NO: V202107, address: wuhan university in Wuhan, China.
The present invention aims at solving the problem of severe acute respiratory syndrome coronavirus (SARS-CoV-2) difficult to prevent and treat, the application of new coronavirus strain in preparing positive milk or serum containing new coronavirus antibody, using the prepared antigen to immunize milk cow to produce immune serum and immune milk containing specific antibody for resisting SARS-CoV-2 virus, and using the obtained new coronavirus immune milk to purify Igs protein for preparing biological preparation for treating or preventing SARS-CoV-2 infection.
In order to achieve the purpose, the invention adopts the following technical measures:
an isolated novel coronavirus strain which has been delivered to the China center for type culture Collection at 04.01.2021, under the taxonomic nomenclature: SARS-CoV-2/ZY38-1, accession number: CCTCC NO: V202107, address: wuhan university in Wuhan, China.
The application of the novel coronavirus strain in preparing positive milk or serum containing the specific antibody of the novel coronavirus, wherein the accession number of the novel coronavirus is EPI _ ISL _ 486645; the application process comprises injecting inactivated new coronavirus strain into cow via neck or buttocks muscle to obtain milk or serum containing new coronavirus antibody positive. The novel coronavirus has a deposit number of: CCTCC NO: V202107, address: wuhan university in Wuhan, China.
In the above application, preferably, the inactivated new coronavirus is prepared into an immune preparation to immunize a cow, and the inactivated new coronavirus is centrifuged to remove cell debris, and then concentrated to obtain a high-concentration antigen;
preparation of an aqueous phase: adding 2% -4% of Tween 80 into the concentrated antigen;
preparing an oil phase: 5-6% of span 85 and 1-2% of aluminum stearate are added into the macro152 white oil, and sterilization is carried out;
and mixing the water phase and the oil phase according to the proportion of 3: 2-4: 3 to obtain the new coronavirus immune preparation.
The protection scope of the invention also includes:
the milk or serum prepared by the method is used for evaluating a novel coronavirus animal model, and the model is constructed by infecting a mouse with SARS-CoV-2/WBP-1.
The milk prepared by the method is prepared into a drinking medicament for neutralizing the novel coronavirus.
The milk or serum prepared by the method can be used for preparing medicines for treating or preventing novel coronavirus infection.
The milk or serum prepared by the method is used for preparing novel coronavirus Igs antibodies, and the antibody protein is used for preparing medicaments for treating or preventing novel coronavirus infection.
Compared with the prior art, the invention has the following advantages:
1. the novel coronavirus can obtain a large amount of immune milk after immunizing a cow, and the immune milk and serum both contain high-content antibodies, can be used as an antibody source of a preparation for preventing and treating new coronary pneumonia, makes up for the limitation of the source of recovered plasma of the new coronary pneumonia, and can be more widely applied to the new coronary pneumonia caused by the novel coronavirus.
2. The immune serum and the immune milk contain high-concentration specific antibody aiming at SARS-CoV-2, can effectively neutralize virus, prevent the virus from invading cells, and have obvious effect of resisting SARS-CoV-2 virus.
3. After the Igs antibody purified by the novel coronavirus immune milk is injected into a mouse, the death rate of the mouse infected by the new coronavirus can be remarkably reduced, the influence of the new coronavirus infection on the weight reduction of the mouse is reduced, and the virus content in the lung tissue of the mouse is reduced.
Drawings
FIG. 1 is a western-blot assay of RBD protein expression.
FIG. 2 immunomilk and serum samples New coronavirus ZY38-1 neutralizing antibody titer plaque plots.
FIG. 3 is a schematic representation of the effect of immunized milk on the body weight of mice infected with SARS-CoV-2/WBP-1 virus.
FIG. 4 is a schematic representation of the effect of immune milk on the survival of mice infected with SARS-CoV-2/WBP-1 virus.
FIG. 5 is a schematic diagram showing the effect of immunized milk on the viral load of lung tissue of SARS-CoV-2/WBP-1 virus-infected mice.
Detailed Description
The test methods and conditions in the examples of the present invention are conventional methods unless otherwise specified. These examples are only for illustrating the present invention, and the scope of the present invention is not limited by these examples. The technical scheme of the invention is a conventional scheme in the field if no special description is provided; the reagents or materials are commercially available, unless otherwise specified. All tests related to the live SARS-CoV-2 virus were performed in the biosafety third-level laboratory (ABSL 3).
Example 1:
preparation of milk and serum containing novel coronavirus antibodies:
the sequence of the novel coronavirus strain is listed in a GISAID database submitted to No. 7/10 of 2020, the login number is EPI _ ISL _486645, and the preservation number in the China center for type culture Collection is CCTCC NO: V202107; in the present invention, the virus is simply referred to as novel coronavirus ZY 38-1.
1. Propagation culture and inactivation of novel coronavirus ZY38-1
(1) Cell culture:
VERO cells are cultured by DMEM containing 10% FBS for about 48 hours for passage;
cell passage: when in passage, the mixture is digested by 0.25 percent of pancreatin for about 10 minutes.
The method comprises the following specific steps:
sucking old culture solution in a culture vessel by using a dropper or a pipette, and washing residual old culture medium by using a DMEM (DMEM) culture medium without serum;
adding 1-2mL of digestive juice (0.25% pancreatin) into the flask, and gently shaking the flask to make the digestive juice flow over all cell surfaces;
when the cells are withdrawn and the processes become round or the intercellular spaces increase, the digestion should be terminated immediately (the digestion solution is aspirated or poured off, a small amount of fresh culture solution containing serum is added to terminate the digestion) under an inverted microscope;
sucking the culture solution in the bottle by using a pipette, repeatedly blowing and beating the digested cells to enable the digested cells to be detached from the wall and dispersed to form cell suspension;
counting, subpackaging into new culture bottles, and supplementing a certain amount of fresh culture solution containing serum;
covering with bottle cap, screwing up, and slightly rotating for CO2Introducing gas, and returning CO to the culture flask2An incubator.
(2) Proliferation of novel coronavirus ZY 38-1:
inoculating the digested Vero cells into a cell culture bottle, and placing the cell culture bottle at 37 ℃ in 5% CO2Culturing in a constant temperature incubator until a monolayer of cells grows out;
inoculating-80 deg.C-preserved novel coronavirus ZY38-10.1mL into culture flask with single layer Vero cells, and culturing at 37 deg.C with 5% CO2Incubating for 1h in a constant-temperature incubator;
carefully aspirate the virus incubation by pipette, add 10mL of DMEM cell maintenance medium containing 2% FBS, 5% CO at 37 deg.C2Culturing in a constant temperature incubator for 48-72 h;
observing the cell state every day, and harvesting virus cell proliferation liquid when more than 80% of cells have lesions; the obtained new coronavirus solution has a virus titer of 106.5TCID50/mL。
(3) Inactivation of SARS-CoV-2 virus and verification of inactivation effect:
virus inactivation: the new coronavirus propagated by the cells is inactivated twice by beta-propiolactone. The specific method is that one thousandth of beta-propiolactone is inactivated at 4 ℃ for 24 hours, and the beta-propiolactone is degraded at 37 ℃ for 6 hours.
And (3) inactivation effect verification: and inoculating the inactivated virus to Vero, observing for 70 hours, collecting supernatant, performing blind transmission for three generations, and preventing cells from generating lesions. Further, the inactivated virus solution is inoculated to a mouse in an abdominal cavity, and the mouse is observed for 70 hours without any adverse reaction, which indicates that the inactivation is thorough and can be used for the next step of antigen preparation.
2. Novel coronavirus antigen preparation
And (3) centrifuging the inactivated and qualified new coronavirus liquid to remove cell debris, and concentrating by adopting a membrane with the aperture of 100KD for 20 times to obtain the high-concentration antigen.
Preparation of an aqueous phase: to the concentrated antigen was added 2% tween 80.
Preparing an oil phase: adding 6% span 85 and 1% aluminum stearate into macro152 white oil, and sterilizing at 116 deg.C for 30 min.
And mixing the water phase and the oil phase according to the proportion of 4:3 to obtain the neocoronavirus oil emulsion immune antigen.
3. Prepared coronavirus oil emulsion antigen immune milk cow
Animal immunization: the prepared antigen is injected into the neck and hip muscles of the dairy cattle for immunization, 16 cattle are immunized, 6mL of the antigen is immunized in each cattle, the immunization is carried out once every 14 days, the immunization is carried out for 4 times totally, and no adverse reaction occurs in the immunized cattle.
Collecting and processing samples: blood samples and milk samples of the immunized cows are collected at different time points after immunization respectively to carry out novel coronavirus antibody detection. The blood sample collection adopts a tail vein blood collection method, a disposable syringe is used for aseptically collecting 3-5mL of non-anticoagulated blood, the blood sample is kept still to separate out serum, the blood sample can not be shaken violently to avoid hemolysis, the blood sample is sent to a laboratory to be separated into serum immediately, and the blood sample which can not be separated immediately needs to be refrigerated in time (4 ℃).
Example 2:
determination of specific antibody levels in immune milk and immune serum
1. Expression and purification of novel coronavirus RBD antigen protein
Through the design of expression elements and the reconstruction of vectors, a novel coronavirus RBD gene is inserted into a pCMV3 expression vector to construct a pCMV3-RBD-his eukaryotic expression vector, and a target protein is obtained through transient expression in 293T suspension cells. 1.1 construction of pCMV3-RBD-his plasmid
Extracting inactivated ZY38-1 virus RNA and reverse transcription amplification virus cDNA, using the cDNA template for RBD fragment amplification, and amplifying a primer RBD-F: 5'-ATGAGGGTCCAACCAACAGAGAGC-3'; 5'-GAAGTTCAC ACACTTGTTCTTCAC-3' as RBD-R. In order to facilitate the subsequent purification of RBD protein, a 6 XHIS sequence is added at the rear end of the RBD gene to obtain the RBD-HIS gene. And carrying out double enzyme digestion on the pCMV3 empty vector and the RBD-his gene by using KpnI and XbaI, and connecting the enzyme-digested fragment with the vector to obtain a recombinant plasmid. The recombinant plasmid is transformed into escherichia coli DH5a competent cells, and cloning screening and sequencing identification are carried out to obtain the correct recombinant plasmid pCMV 3-RBD-his. Carrying out amplification culture on Escherichia coli with positive pCMV3-RBD-his plasmid, extracting non-endotoxin pCMV3-RBD-his plasmid by using MN plasmid extraction kit, adjusting the concentration of the extracted plasmid to 1 ug/mu L, and subpackaging at-80 ℃ for storage.
1.2 recovery and culture of suspension 293T cells
The 293T suspension cell frozen stock solution is thawed in a water bath at 37 ℃,20 mL of culture medium is added into a 100mL cell shaking flask, all the thawed cells are transferred into a cell flask, and the cells are gently mixed. The resuspended cells are cultured in a constant temperature shaker at 37 ℃ and 5% CO2 and rotation speed of 150-175rp m, the cell activity within 3-5 days is detected, passage is carried out for 2-3 times, and transfection is carried out when the cell activity is more than 90%.
1.3 transfection of cells
Taking 20 mu L of the pCMV3-RBD-his plasmid preserved in the step 1.1 to 150mmol of NaCl solution, wherein the final volume is 1mL, and the plasmid content is 20 ug; meanwhile, diluting 100 mu L of transfection reagent by using 150mmol of NaCl to the total volume of 1mL, standing alone for five minutes, mixing the 2 solutions uniformly, and dropwise adding the mixed solution into the shake flask of cells with the cell activity of more than 90%. And (5) detecting the expression quantity of the target protein in the cells and the supernatant after transfection for 48-72 h.
1.4 expression product analysis
Transfecting 293T cells with pCMV3-RBD-his, collecting protein sample samples in cultured cells and supernatant at four time points of 24h, 36 h, 48 h and 72h, purifying target protein by using a nickel column, and carrying out Western-blot detection to prove that the RBD protein starts to express at 24h and the RBD protein content in the cultured supernatant is highest at 72h, as shown in figure 1.
Determining the concentration of the purified RBD protein by using a Bradford protein concentration determination kit, diluting the obtained RBD protein by 50 times by using coating solution, coating a 96-well polystyrene reaction plate by 100 mu L per well, and incubating overnight at 2-8 ℃; removing the coating solution, adding sealing solution, sealing at 37 deg.C for 40 min; discarding the blocking solution, washing with PBST for 3 times, diluting RBD protein specific labeled monoclonal antibody 1000 times with diluent (5% defatted milk powder PBST), adding 100 μ L per well, and incubating at 37 deg.C for 40 min; sucking dry, washing with PBST for 3 times, adding 100 μ L TMB working solution into each well, keeping away from light for 10min, adding 50 μ L stop solution, and determining OD630And (4) light absorption value. The result shows that the RBD protein after purification has specific ELISA reaction.
2. ELISA detection steps of specific antibodies of the novel coronavirus ZY 38-1:
(1) and (3) taking the novel coronavirus RBD protein expressed and purified in the step (1) as an antigen, coating a 96-hole polystyrene reaction plate by using 100 ng/hole, incubating at 4 ℃ for 16h, removing a coating solution, drying an ELISA coating plate, adding a sealing solution, and sealing at 37 ℃ for 2 h. Removing the blocking solution, beating dry the ELISA coated plate, adding 180 muL of PBST washing solution into each hole, washing for 3 times, beating dry the ELISA coated plate, drying, and placing at 4 ℃ for later use.
(2) Centrifuging the blood sample to be detected at 4 deg.C and 3000rpm for 10min, centrifuging the milk sample to be detected at 4 deg.C and 8000 rpm for 20min, collecting the intermediate layer, and storing at-20 deg.C.
(3) The stored serum and milk samples were diluted 1:40 with a diluent (probiotics, GmbH, Wuhan Ke.), and added to the antigen-coated plate at 100. mu.L/well. Incubating in 37 ℃ incubator for 30min, discarding coating solution, adding 180 μ L PBST washing solution to each well, washing for 5 times, and beating dry ELISA coated plate.
(4) Diluting rabbit anti-bovine IgG antibody labeled by horseradish peroxidase to 1:16000 with a secondary antibody protective agent (limited pre-biological member of the Wuhan family), adding into an ELISA coated plate incubated with the primary antibody, incubating for 30min at 37 ℃ in an incubator at 100 mu L/hole, discarding secondary antibody diluent, adding 180 mu L of PBST washing solution into each hole, washing for 5 times, and patting dry the ELISA coated plate.
(5) 50. mu.L of TMB color developing solution A, 50. mu. L, B, was added to each well, and the reaction was stopped by keeping the wells away from light at 37 ℃ for 10min and then adding 50. mu.L of stop solution to each well.
(6) The reaction plate after termination is placed in a microplate reader, and the OD of each well is read630nmAnd (4) data.
As shown in tables 1 and 2, the antigen prepared from SARS-CoV-2 virus can stimulate host to produce antibodies against the novel coronavirus after immunizing cow, and can detect the novel coronavirus antibodies in both the serum and the milk of immunized cow, and the novel coronavirus antibodies can still be detected in the milk 76 days after the fourth immunization, and the serum sample also contains high antibody level.
TABLE 1 SARS-CoV-2 specific antibody levels in immunized milk
Note: "-" indicates that the cow was in the dry period and no sample was taken.
TABLE 2 SARS-CoV-2 specific antibody levels in immune sera
Note: "-" indicates that the cow was in the dry period and no sample was taken.
Example 3:
neutralizing antibody titer of immune milk and immune serum
The method adopts a trace neutralization experiment for reducing plaque of the new coronavirus to detect the titer of a neutralizing antibody of an antibody in immune milk and immune serum to the new coronavirus, and comprises the following specific steps:
(1) the Vero cells with good growth state are subcultured to a 12-hole cell culture plate with 3-5E 5/hole, and grow into a compact single layer the next day.
(2) Serum and milk samples treated and stored at-20 ℃ in example 2 were inactivated for 30min at 56 ℃.
(3) Serum and milk samples were diluted in 24-well plates in serum-free DMEM medium at double ratios, and 24-well plates were prepared for the number of samples, 4 samples per plate, and an additional virus back-drop control was added.
(4) The first column of each well plate was loaded with 441. mu.L or 405. mu.L of DMEM, and the other wells were loaded with 300. mu.L.
(5) Add 9. mu.L of serum or 45. mu.L of milk samples to the first row of wells, i.e.the total volume of liquid in each well was 450. mu.L, mix well with shaking.
(6) Taking 150 mu L from the first row to the second row by using a row gun, blowing, beating, vibrating and uniformly mixing; the tip was changed, 150. mu.L was taken from the second row to the third row, the operation was repeated until the sixth row, and finally 150. mu.L was taken from the sixth row and discarded.
(7) And calculating the volume of the required virus dilution liquid and virus freezing liquid according to the number of samples, adding 3-5mL of dilution liquid on the basis of the required volume, and taking DMEM + 2.5% FBS with the corresponding volume into a 50mL centrifugal tube.
(8) A frozen stock of the novel strain of coronavirus ZY38-1 was removed from a freezer at-150 deg.C, inserted into the buoy as soon as possible and placed in a box filled with tap water, and the buoy was removed from time to accelerate thawing.
(9) Taking the virus freezing medium with the required volume to DMEM diluent, wherein the virus titer after dilution is 400 pfu/mL; if the volume of the required virus frozen stock solution is less than 10 mu L, the virus frozen stock solution is firstly diluted by 10 times in a 2mL centrifugal tube.
(10) And (3) taking 300 mu L of virus diluent and adding the virus diluent into serum or milk diluent, and changing the gun head for each diluent to avoid the virus from not acting with the serum or milk due to collision with the hole wall.
(11) After adding the virus diluent, each 24-well plate is slightly tapped, shaken and mixed evenly, and is placed in an incubator for incubation for 1h at 37 ℃, the well plates are not required to be stacked as much as possible, and if the space is limited, more than two layers are not required to be stacked.
(12) Absorbing the culture medium in the Vero cell culture plate, and adding 500 mu L of serum or mixed solution of milk and virus; incubate at 37 ℃ for 1h in an incubator with as little plates stacked as possible, if space is limited, no more than two layers stacked.
(13) The mixture was aspirated off, 1mL of DMEM + 2.5% FBS + 0.9% methylcellulose was added to each well, and the mixture was placed in an incubator for 3-4 days.
(14) Add 1mL of 8% formaldehydee-PBS to each well and fix for more than 1 h.
(15) The fixative was poured off and washed once with single distilled water.
(16) Adding 0.5% crystal violet for dyeing for 10min, washing with single distilled water for three times, and taking pictures and counting plaques.
As a result, as shown in tables 3 and 4, both the immune serum and the immune milk were effective in inhibiting the proliferation of the novel coronavirus ZY38-1 on cells. After 14 days of four-time immunization, the neutralizing antibody titer of the immune bovine serum reaches 1: 12150; the neutralizing antibody titer in the immune milk can reach 1:270 by more than 85 percent.
TABLE 3 neutralization potency of SARS-CoV-2 specific antibodies in immune milk
TABLE 4 neutralization potency of SARS-CoV-2 specific antibodies in immune sera
Example 4:
evaluation of antiviral effect of novel coronavirus ZY38-1 immune milk in mice:
obtaining mouse adaptive strain SARS-CoV-2:
SARS-CoV-2 strain (NC-045512.2) separated from human sample is inoculated into female B ALB/c mouse of 10 months age by nasal drip, the infection dose is 50ul, the virus content is 2.3X 105PFU. After 3 days of infection, the mice were dissected to collect lung tissue, homogenized, centrifuged at 12000rpm for 5min, and the supernatant was collected as mouse-adapted passage new coronavirus passage 1. The lung tissue homogenate of the 1 st generation was inoculated into 4-6 week-old mice, and 3 days later, the lungs were harvested and homogenized to obtain virus fluid of the 2 nd generation. The mice aged 4-6 weeks were serially passaged to obtain 11 th generation virus solution. During the passage, the 9 th mouse died due to virus infection for the first time, and the mice died after passing through 14 generations.
Diluting the supernatant of the 11 th generation lung tissue homogenate by 103、104Inoculating the strain to VERO cells in a doubling manner, incubating at 37 ℃ for 1h, discarding virus liquid, flushing the cells, covering 1% agarose gel phenol-free DMEM culture medium, culturing for 2d, picking cell plaques by using an aseptic gun head to obtain purified viruses, inoculating the purified strains to the cells again for plaque purification, finally obtaining a mouse adaptive strain WBP-1 which is stable and lethal to mice, and preserving the 11 th generation mouse adaptive stable strains. The strain is delivered to China Center for Type Culture Collection (CCTCC) for preservation at 8 months and 17 days in 2020, and is classified and named as follows: novel coronavirus SARS-CoV-2/WBP-1, the preservation number is CCTCC NO: v202031, address: wuhan university in Wuhan, China.
And (3) carrying out whole genome sequencing on the SARS-CoV-2/WBP-1 mouse adaptive strain obtained by purification, wherein the sequence is shown as SEQ ID NO. 1.
The novel coronavirus RT-PCR detection and identification primers are as follows:
F:5’-CCAGATGATTTTACAGGCTGCGTTA-3’
R:5’-TGTCAAGAATCTCAAGTGTCTGTGGATC-3’
the length of the amplified product fragment is 484 bp.
The preserved mouse adaptive strain WBP-1 is purified on VERO cells for 3 times, and then is continuously passaged on the VERO cells for 3 times, each generation of virus can kill mice, and the virus is not mutated by PCR and is stable in passage.
2. The purification of Igs antibodies in immune milk and non-immune milk comprises the following specific experimental steps:
(1) milk pretreatment: storage of milk at-20 ℃ milk was thawed at 4 ℃, centrifuged at 7000rpm for 30min at 4 ℃, the upper fat layer was carefully removed, the lower liquid layer was transferred to a new centrifuge tube and filtered again to remove lipids as much as possible.
(2) The new crown immune milk and non-immune milk firstly remove casein by an isoelectric point precipitation method: adding PBS with the same volume as the filtered and degreased milk, adjusting the pH value to 4.6, carrying out water bath at 40 ℃ for 30min, continuously stirring, standing overnight at 4 ℃, centrifuging at 7000rp m and 4 ℃ for 30min, removing precipitates, and transferring the supernatant to a clean beaker.
(3) Precipitating the antibody by an ammonium sulfate method: adding saturated ammonium sulfate with the same volume as that of the supernatant and having a pH of 7.4, stirring for 30min by a magnetic stirrer, standing overnight at 4 ℃, centrifuging for 30min at 7000rpm and 4 ℃, removing the supernatant, and re-dissolving the precipitate with 200mL of PBS.
(4) Dialysis desalting of reconstituted protein: centrifuging the above re-dissolved protein sample at 12000rpm at 4 deg.C for 30min to remove insoluble protein precipitate, loading the supernatant into dialysis bag for desalting, dialyzing with 10mmol of Tris-HCl (pH 9.0) for 48-72h, transferring the protein sample from the dialysis bag into a centrifuge tube, centrifuging at 12000rpm for 30min to remove protein precipitate, and transferring the supernatant into a new centrifuge tube.
(5) Protein G sepharose purification of antibodies: and (3) enabling the supernatant obtained in the step (4) to pass through a Protein G agarose gel column, washing the purified antibody after passing through the column by using precooled TBS to remove unbound and non-specifically bound proteins, eluting the antibody by using 10mL of 50mM glycine with the pH value of 2.7 after washing, and collecting eluent.
(6) Concentration of purified antibody: centrifuging and concentrating the eluate with ultrafiltration tube with molecular weight cut-off of 10kD, and packaging the concentrated sample into 1.5mL centrifuge tubes, each having a volume of 1mL, and storing at-80 deg.C
(7) Determination of purified antibody protein concentration: and (3) measuring the content of the purified and concentrated antibody protein by using a Bradford protein concentration measuring kit, and adjusting the concentrations of the immune milk and the non-immune purified sample to be consistent, wherein the content of the antibody protein is 5 mg/mL.
3. Mouse animal experiments:
(1) the 20 BALB/c mice of 6-8 weeks old were randomly divided into 4 groups of 5 mice each, one group of immune milk purified antibody protein gavage (IM-i.a), one group of immune milk purified antibody protein intraperitoneal injection (IM-i.p), and the other 2 groups of non-immune milk purified antibody protein gavage (NIM-i.a) and intraperitoneal injection (NIM-i.p), respectively. Gavage is performed once a day, and each mouse has 200 mu L; intraperitoneal injections were given once a day, 200 μ L per mouse.
(2) After continuous 5 days of gastric lavage and injection, mice were infected with the novel coronavirus SARS-CoV-2/WBP-1 virus, and all mice were infected with 5 LD by nasal drip50WBP-1 New coronavirus.
(3) The mice are weighed before and after infection respectively, the weight and symptoms of the mice are observed and recorded every day, padding, drinking water and food are replaced and added at regular time, and dead mice are taken out in time for dissection until the experiment is completed.
(4) After 5 days of challenge, all the surviving mice were sacrificed, lung, trachea and turbinate bone tissues were dissected and removed, and the content of the novel coronavirus SARS-CoV-2/WBP-1 virus in the tissue samples was determined by RT-PCR.
(5) And drawing a weight change curve, a survival rate curve and a tissue virus vector graph according to the statistical result.
The experimental results are as follows:
the results of the body weight change of mice are shown in fig. 3 and table 5, and the immune milk injection group (IM-i.p) can significantly reduce the body weight loss caused by SARS-CoV-2 virus infection compared to the non-immune milk injection group (NIM-i.p); meanwhile, the weight reduction tendency of the immunized milk lavage group (IM-i.a) is lower than that of the non-immunized milk lavage group (NIM-i.a). The weight reduction tendency of the immune milk is lower than that of non-immune milk whether the milk is perfused or injected. The weight percentage of mice was calculated as mean weight of mice in each group at different times after infection with virus/mean weight of mice in each group at day 0 of infection%
TABLE 5 Effect of immune milk purified antibody protein on mouse body weight following SARS-CoV-2/WBP-1 Virus infection
The results of the mouse survival rate are shown in fig. 4 and table 6, and the mouse survival rate was calculated by counting the number of surviving mice per group/total number of infected mice per group 100%, 100% of mice in the immunized milk injection group (IM-i.p) survived, 40% of mice in the immunized milk gavage group (IM-i.a) survived, and 20% of mice in both the non-immunized milk injection group (NIM-i.p) and the gavage group (NIM-i.a).
TABLE 6 influence of immune milk purified antibody protein on survival of mice after SARS-CoV-2/WBP-1 Virus infection
As shown in FIG. 5 and Table 7, the SARS-CoV-2 viral load in different tissue samples of mice was detected, and the immune milk injection group (IM-i.p) turbinate (turbinate) could not detect the novel coronavirus SARS-CoV-2/WBP-1, and the other 3 groups could detect the novel coronavirus SARS-CoV-2/WBP-1; the content of SARS-CoV-2 virus in the immunized milk injection group (IM-i.p) trachea (trachea) and lung (lung) was significantly lower than in the other 3 groups. In the turbinate and trachea, the SARS-CoV-2 virus content in the immunized milk gavage group (I M-i.a) was also lower than that in the non-immunized milk injection group (NIM-i.p) and the gavage group (NIM-i.a).
TABLE 7 Effect of immune milk purified antibody protein on New coronavirus load in lung, trachea and turbinate tissues of mice after SARS-CoV-2/WBP-1 Virus infection (log10copies/mL)
The above results indicate that the immune milk has a significant effect against the novel coronavirus SARS-CoV-2/WBP-1 in mice.
Sequence listing
<110> university of agriculture in Huazhong
WUHAN ACADEMY OF AGRICULTURAL SCIENCES
WUHAN KEQIAN BIOLOGICAL Co.,Ltd.
<120> preparation method and application of novel coronavirus, specific antibody-containing milk or serum produced by immune dairy cow thereof
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 29218
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
tgagtgcact aagcatgcag ccgagtgaca gccacacaga ttttaaagtt cgtttagaga 60
acagatctac aagagatcga aagttggttg gtttgttacc tgggaaggta taaaccaacc 120
aactttcgat ctcttgtaga tctgttctct aaacgaactt taaaatctgt gtggctgtca 180
ctcggctgca tgcttagtgc actcacgcag tataattaat aactaattac tgtcgttgac 240
aggacacgag taactcgtct atcttctgca ggctgcttac ggtttcgtcc gtgttgcagc 300
cgatcatcag cacatctagg tttcgtccgg gtgtgaccga aaggtaagat ggagagcctt 360
gtccctggtt tcaacgagaa aacacacgtc caactcagtt tgcctgtttt acaggttcgc 420
gacgtgctcg tacgtggctt tggagactcc gtggaggagg tcttatcaga ggcacgtcaa 480
catcttaaag atggcacttg tggcttagta gaagttgaaa aaggcgtttt gcctcaactt 540
gaacagccct atgtgttcat caaacgttcg gatgctcgaa ctgcacctca tggtcatgtt 600
atggttgagc tggtagcaga actcgaaggc attcagtacg gtcgtagcgg tgagacactt 660
ggtgtccttg tccctcatgt gggcgaaata ccagtggctt accgcaaggt tcttcttcgt 720
aagaacggta ataaaggagc tggtggccat agttacggcg ccgatctaaa gtcatttgac 780
ttaggcgacg agcttggcac tgatccttat gaagattttc aagaaaactg gaacactaaa 840
catagcagtg gtgttacccg tgaactcatg cgtgagctta acggaggggc atacactcgc 900
tatgtcgata acaacttctg tggccctgat ggctaccctc ttgagtgcat taaagacctt 960
ctagcacgtg ctggtaaagc ttcatgcact ttgtccgaac aactggactt tattgacact 1020
aagaggggtg tatactgctg ccgtgaacat gagcatgaaa ttgcttggta cacggaacgt 1080
tctgaaaaga gctatgaatt gcagacacct tttgaaatta aattggcaaa gaaatttgac 1140
accttcaatg gggaatgtcc aaattttgta tttcccttaa attccataat caagactatt 1200
caaccaaggg ttgaaaagaa aaagcttgat ggctttatgg gtagaattcg atctgtctat 1260
ccagttgcgt caccaaatga atgcaaccaa atgtgccttt caactctcat gaagtgtgat 1320
cattgtggtg aaacttcatg gcagacgggc gattttgtta aagccacttg cgaattttgt 1380
ggcactgaga atttgactaa agaaggtgcc actacttgtg gttacttacc ccaaaatgct 1440
gttgttaaaa tttattgtcc agcatgtcac aattcagaag taggacctga gcatagtctt 1500
gccgaatacc ataatgaatc tggcttgaaa accattcttc gtaagggtgg tcgcactatt 1560
gcctttggag gctgtgtgtt ctcttatgtt ggttgccata acaagtgtgc ctattgggtt 1620
ccacgtgcta gcgctaacat aggttgtaac catacaggtg ttgttggaga aggttccgaa 1680
ggtcttaatg acaaccttct tgaaatactc caaaaagaga aagtcaacat caatattgtt 1740
ggtgacttta aacttaatga agagatcgcc attattttgg catctttttc tgcttccaca 1800
agtgcttttg tggaaactgt gaaaggtttg gattataaag cattcaaaca aattgttgaa 1860
tcctgtggta attttaaagt tacaaaagga aaagctaaaa aaggtgcctg gaatattggt 1920
gaacagaaat caatactgag tcctctttat gcatttgcat cagaggctgc tcgtgttgta 1980
cgatcaattt tctctcgcac tcttgaaact gctcaaaatt ctgtgcgtgt tttacagaag 2040
gccgctataa caatactaga tggaatttca cagtattcac tgagactcat tgatgctatg 2100
atgttcacat ctgatttggc tactaacaat ctagttgtaa tggcctacat tacaggtggt 2160
gttgttcagt tgacttcgca gtggctaact aacatctttg gcactgttta tgaaaaactc 2220
aaacccgtcc ttgattggct tgaagagaag tttaaggaag gtgtagagtt tcttagagac 2280
ggttgggaaa ttgttaaatt tatctcaacc tgtgcttgtg aaattgtcgg tggacaaatt 2340
gtcacctgtg caaaggaaat taaggagagt gttcagacat tctttaagct tgtaaataaa 2400
tttttggctt tgtgtgctga ctctatcatt attggtggag ctaaacttaa agccttgaat 2460
ttaggtgaaa catttgtcac gcactcaaag ggattgtaca gaaagtgtgt taaatccaga 2520
gaagaaactg gcctactcat gcctctaaaa gccccaaaag aaattatctt cttagaggga 2580
gaaacacttc ccacagaagt gttaacagag gaagttgtct tgaaaactgg tgatttacaa 2640
ccattagaac aacctactag tgaagctgtt gaagctccat tggttggtac accagtttgt 2700
attaacgggc ttatgttgct cgaaatcaaa gacacagaaa agtactgtgc ccttgcacct 2760
aatatgatgg taacaaacaa taccttcaca ctcaaaggcg gtgcaccaac aaaggttact 2820
tttggtgatg acactgtgat agaagtgcaa ggttacaaga gtgtgaatat cacttttgaa 2880
cttgatgaaa ggattgataa agtacttaat gagaagtgct ctgcctatac agttgaactc 2940
ggtacagaag taaatgagtt cgcctgtgtt gtggcagatg ctgtcataaa aactttgcaa 3000
ccagtatctg aattacttac accactgggc attgatttag atgagtggag tatggctaca 3060
tactacttat ttgatgagtc tggtgagttt aaattggctt cacatatgta ttgttctttc 3120
taccctccag atgaggatga agaagaaggt gattgtgaag aagaagagtt tgagccatca 3180
actcaatatg agtatggtac tgaagatgat taccaaggta aacctttgga atttggtgcc 3240
acttctgctg ctcttcaacc tgaagaagag caagaagaag attggttaga tgatgatagt 3300
caacaaactg ttggtcaaca agacggcagt gaggacaatc agacaactac tattcaaaca 3360
attgttgagg ttcaacctca attagagatg gaacttacac cagttgttca gactattgaa 3420
gtgaatagtt ttagtggtta tttaaaactt actgacaatg tatacattaa aaatgcagac 3480
attgtggaag aagctaaaaa ggtaaaacca acagtggttg ttaatgcagc caatgtttac 3540
cttaaacatg gaggaggtgt tgcaggagcc ttaaataagg ctactaacaa tgccatgcaa 3600
gttgaatctg atgattacat agctactaat ggaccactta aagtgggtgg tagttgtgtt 3660
ttaagcggac acaatcttgc taaacactgt cttcatgttg tcggcccaaa tgttaacaaa 3720
ggtgaagaca ttcaacttct taagagtgct tatgaaaatt ttaatcagca cgaagttcta 3780
cttgcaccat tattatcagc tggtattttt ggtgctgacc ctatacattc tttaagagtt 3840
tgtgtagata ctgttcgcac aaatgtctac ttagctgtct ttgataaaaa tctctatgac 3900
aaacttgttt caagcttttt ggaaatgaag agtgaaaagc aagttgaaca aaagatcgct 3960
gagattccta aagaggaagt taagccattt ataactgaaa gtaaaccttc agttgaacag 4020
agaaaacaag atgataagaa aatcaaagct tgtgttgaag aagttacaac aactctggaa 4080
gaaactaagt tcctcacaga aaacttgtta ctttatattg acattaatgg caatcttcat 4140
ccagattctg ccactcttgt tagtgacatt gacatcactt tcttaaagaa agatgctcca 4200
tatatagtgg gtgatgttgt tcaagagggt gttttaactg ctgtggttat acctactaaa 4260
aaggctggtg gcactactga aatgctagcg aaagctttga gaaaagtgcc aacagacaat 4320
tatataacca cttacccggg tcagggttta aatggttaca ctgtagagga ggcaaagaca 4380
gtgcttaaaa agtgtaaaag tgccttttac attctaccat ctattatctc taatgagaag 4440
caagaaattc ttggaactgt ttcttggaat ttgcgagaaa tgcttgcaca tgcagaagaa 4500
acacgcaaat taatgcctgt ctgtgtggaa actaaagcca tagtttcaac tatacagcgt 4560
aaatataagg gtattaaaat acaagagggt gtggttgatt atggtgctag attttacttt 4620
tacaccagta aaacaactgt agcgtcactt atcaacacac ttaacgatct aaatgaaact 4680
cttgttacaa tgccacttgg ctatgtaaca catggcttaa atttggaaga agctgctcgg 4740
tatatgagat ctctcaaagt gccagctaca gtttctgttt cttcacctga tgctgttaca 4800
gcgtataatg gttatcttac ttcttcttct aaaacacctg aagaacattt tattgaaacc 4860
atctcacttg ctggttccta taaagattgg tcctattctg gacaatctac acaactaggt 4920
atagaatttc ttaagagagg tgataaaagt gtatattaca ctagtaatcc taccacattc 4980
cacctagatg gtgaagttat cacctttgac aatcttaaga cacttctttc tttgagagaa 5040
gtgaggacta ttaaggtgtt tacaacagta gacaacatta acctccacac gcaagttgtg 5100
gacatgtcaa tgacatatgg acaacagttt ggtccaactt atttggatgg agctgatgtt 5160
actaaaataa aacctcataa ttcacatgaa ggtaaaacat tttatgtttt acctaatgat 5220
gacactctac gtgttgaggc ttttgagtac taccacacaa ctgatcctag ttttctgggt 5280
aggtacatgt cagcattaaa tcacactaaa aagtggaaat acccacaagt taatggttta 5340
acttctatta aatgggcaga taacaactgt tatcttgcca ctgcattgtt aacactccaa 5400
caaatagagt tgaagtttaa tccacctgct ctacaagatg cttattacag agcaagggct 5460
ggtgaagctg ctaacttttg tgcacttatc ttagcctact gtaataagac agtaggtgag 5520
ttaggtgatg ttagagaaac aatgagttac ttgtttcaac atgccaattt agattcttgc 5580
aaaagagtct tgaacgtggt gtgtaaaact tgtggacaac agcagacaac ccttaagggt 5640
gtagaagctg ttatgtacat gggcacactt tcttatgaac aatttaagaa aggtgttcag 5700
ataccttgta cgtgtggtaa acaagctaca aaatatctag tacaacagga gtcacctttt 5760
gttatgatgt cagcaccacc tgctcagtat gaacttaagc atggtacatt tacttgtgct 5820
agtgagtaca ctggtaatta ccagtgtggt cactataaac atataacttc taaagaaact 5880
ttgtattgca tagacggtgc tttacttaca aagtcctcag aatacaaagg tcctattacg 5940
gatgttttct acaaagaaaa cagttacaca acaaccataa aaccagttac ttataaattg 6000
gatggtgttg tttgtacaga aattgaccct aagttggaca attattataa gaaagacaat 6060
tcttatttca cagagcaacc aattgatctt gtaccaaacc aaccatatcc aaacgcaagc 6120
ttcgataatt ttaagtttgt atgtgataat atcaaatttg ctgatgattt aaaccagtta 6180
actggttata agaaacctgc ttcaagagag cttaaagtta catttttccc tgacttaaat 6240
ggtgatgtgg tggctattga ttataaacac tacacaccct cttttaagaa aggagctaaa 6300
ttgttacata aacctattgt ttggcatgtt aacaatgcaa ctaataaagc cacgtataaa 6360
ccaaatacct ggtgtatacg ttgtctttgg agcacaaaac cagttgaaac atcaaattcg 6420
tttgatgtac tgaagtcaga ggacgcgcag ggaatggata atcttgcctg cgaagatcta 6480
aaaccagtct ctgaagaagt agtggaaaat cctaccatac agaaagacgt tcttgagtgt 6540
aatgtgaaaa ctaccgaagt tgtaggagac attatactta aaccagcaaa taatagttta 6600
aaaattacag aagaggttgg ccacacagat ctaatggctg cttatgtaga caattctagt 6660
cttactatta agaaacctaa tgaattatct agagtattag gtttgaaaac ccttgctact 6720
catggtttag ctgctgttaa tagtgtccct tgggatacta tagctaatta tgctaagcct 6780
tttcttaaca aagttgttag tacaactact aacatagtta cacggtgttt aaaccgtgtt 6840
tgtactaatt atatgcctta tttctttact ttattgctac aattgtgtac ttttactaga 6900
agtacaaatt ctagaattaa agcatctatg ccgactacta tagcaaagaa tactgttaag 6960
agtgtcggta aattttgtct agaggcttca tttaattatt tgaagtcacc taatttttct 7020
aaactgataa atattataat ttggttttta ctattaagtg tttgcctagg ttctttaatc 7080
tactcaaccg ctgctttagg tgttttaatg tctaatttag gcatgccttc ttactgtact 7140
ggttacagag aaggctattt gaactctact aatgtcacta ttgcaaccta ctgtactggt 7200
tctatacctt gtagtgtttg tcttagtggt ttagattctt tagacaccta tccttcttta 7260
gaaactatac aaattaccat ttcatctttt aaatgggatt taactgcttt tggcttagtt 7320
gcagagtggt ttttggcata tattcttttc actaggtttt tctatgtact tggattggct 7380
gcaatcatgc aattgttttt cagctatttt gcagtacatt ttattagtaa ttcttggctt 7440
atgtggttaa taattaatct tgtacaaatg gccccgattt cagctatggt tagaatgtac 7500
atcttctttg catcatttta ttatgtatgg aaaagttatg tgcatgttgt agacggttgt 7560
aattcatcaa cttgtatgat gtgttacaaa cgtaatagag caacaagagt cgaatgtaca 7620
actattgtta atggtgttag aaggtccttt tatgtctatg ctaatggagg taaaggcttt 7680
tgcaaactac acaattggaa ttgtgttaat tgtgatacat tctgtgctgg tagtacattt 7740
attagtgatg aagttgcgag agacttgtca ctacagttta aaagaccaat aaatcctact 7800
gaccagtctt cttacatcgt tgatagtgtt acagtgaaga atggttccat ccatctttac 7860
tttgataaag ctggtcaaaa gacttatgaa agacattctc tctctcattt tgttaactta 7920
gacaacctga gagctaataa cactaaaggt tcattgccta ttaatgttat agtttttgat 7980
ggtaaatcaa aatgtgaaga atcatctgca aaatcagcgt ctgtttacta cagtcagctt 8040
atgtgtcaac ctatactgtt actagatcag gcattagtgt ctgatgttgg tgatagtgcg 8100
gaagttgcag ttaaaatgtt tgatgcttac gttaatacgt tttcatcaac ttttaacgta 8160
ccaatggaaa aactcaaaac actagttgca actgcagaag ctgaacttgc aaagaatgtg 8220
tccttagaca atgtcttatc tacttttatt tcagcagctc ggcaagggtt tgttgattca 8280
gatgtggaaa ctaaagatgt tgttgaatgt cttaaattgt cacatcaatc tgacatagaa 8340
gttactggcg atagttgtaa taactatatg ctcacctata acaaagttga aaacatgaca 8400
ccccgtgacc ttggtgcttg tattgactgt agtgcgcgtc atattaatgc gcaggtagca 8460
aaaagtcaca acattgcttt gatatggaac gttaaagatt tcatgtcatt gtctgaacaa 8520
ctacgaaaac aaatacgtag tgctgctaaa aagaataact taccttttaa gttgacatgt 8580
gcaactacta gacaagttgt taatgttgta acaacaaaga tagcacttaa gggtggtaaa 8640
attgttaata attggttgaa gcagttaatt aaagttacac ttgtgttcct ttttgttgct 8700
gctattttct atttaataac acctgttcat gtcatgtcta aacatactga cttttcaagt 8760
gaaatcatag gatacaaggc tattgatggt ggtgtcactc gtgacatagc atctacagat 8820
acttgttttg ctaacaaaca tgctgatttt gacacatggt ttagccagcg tggtggtagt 8880
tatactaatg acaaagcttg cccattgatt gctgcagtca taacaagaga agtgggtttt 8940
gtcgtgcctg gtttgcctgg cacgatatta cgcacaacta atggtgactt tttgcatttc 9000
ttacctagag tttttagtgc agttggtaac atctgttaca caccatcaaa acttatagag 9060
tacactgact ttgcaacatc agcttgtgtt ttggctgctg aatgtacaat ttttaaagat 9120
gcttctggta agccagtacc atattgttat gataccaatg tactagaagg ttctgttgct 9180
tatgaaagtt tacgccctga cacacgttat gtgctcatgg atggctctat tattcaattt 9240
cctaacacct accttgaagg ttctgttaga gtggtaacaa cttttgattc tgagtactgt 9300
aggcacggca cttgtgaaag atcagaagct ggtgtttgtg tatctactag tggtagatgg 9360
gtacttaaca atgattatta cagatcttta ccaggagttt tctgtggtgt agatgctgta 9420
aatttactta ctaatatgtt tacaccacta attcaaccta ttggtgcttt ggacatatca 9480
gcatctatag tagctggtgg tattgtagct atcgtagtaa catgccttgc ctactatttt 9540
atgaggttta gaagagcttt tggtgaatac agtcatgtag ttgcctttaa tactttacta 9600
ttccttatgt cattcactgt actctgttta acaccagttt actcattctt acctggtgtt 9660
tattctgtta tttacttgta cttgacattt tatcttacta atgatgtttc ttttttagca 9720
catattcagt ggatggttat gttcacacct ttagtacctt tctggataac aattgcttat 9780
atcatttgta tttccacaaa gcatttctat tggttcttta gtaattacct aaagagacgt 9840
gtagtcttta atggtgtttc ctttagtact tttgaagaag ctgcgctgtg cacctttttg 9900
ttaaataaag aaatgtatct aaagttgcgt agtgatgtgc tattacctct tacgcaatat 9960
aatagatact tagctcttta taataagtac aagtatttta gtggagcaat ggatacaact 10020
agctacagag aagctgcttg ttgtcatctc gcaaaggctc tcaatgactt cagtaactca 10080
ggttctgatg ttctttacca accaccacaa acctctatca cctcagctgt tttgcagagt 10140
ggttttagaa aaatggcatt cccatctggt aaagttgagg gttgtatggt acaagtaact 10200
tgtggtacaa ctacacttaa cggtctttgg cttgatgacg tagtttactg tccaagacat 10260
gtgatctgca cctctgaaga catgcttaac cctaattatg aagatttact cattcgtaag 10320
tctaatcata atttcttggt acaggctggt aatgttcaac tcagggttat tggacattct 10380
atgcaaaatt gtgtacttaa gcttaaggtt gatacagcca atcctaagac acctaagtat 10440
aagtttgttc gcattcaacc aggacagact ttttcagtgt tagcttgtta caatggttca 10500
ccatctggtg tttaccaatg tgctatgagg cccaatttca ctattaaggg ttcattcctt 10560
aatggttcat gtggtagtgt tggttttaac atagattatg actgtgtctc tttttgttac 10620
atgcaccata tggaattacc aactggagtt catgctggca cagacttaga aggtaacttt 10680
tatggacctt ttgttgacag gcaaacagca caagcagctg gtacggacac aactattaca 10740
gttaatgttt tagcttggtt gtacgctgct gttataaatg gagacaggtg gtttctcaat 10800
cgatttacca caactcttaa tgactttaac cttgtggcta tgaagtacaa ttatgaacct 10860
ctaacacaag accatgttga catactagga cctctttctg ctcaaactgg aattgccgtt 10920
ttagatatgt gtgcttcatt aaaagaatta ctgcaaaatg gtatgaatgg acgtaccata 10980
ttgggtagtg ctttattaga agatgaattt acacctcttg atgttgttag acaatgctca 11040
ggtgttactt tccaaagtgc agtgaaaaga acaaccaagg gtacacacca ctggttgtta 11100
ctcacaattt tgacttcact tttagtttta gtccagagta ctcaatggtc tttgttcttt 11160
tttttgtatg aaaatgcctt tttacctttt gctatgggta ttattgctat gtctgctttt 11220
gcaatgatgt ttgtcaaaca taagcatgca tttctctgtt tgtttttgtt accttctctt 11280
gccactgtag cttattttaa tatggtctat atgcctgcta gttgggtgat gcgtattatg 11340
acatggttgg atatggttga tactagtttg tctggtttta agctaaaaga ctgtgttatg 11400
tatgcatcag ctgtagtgtt actaatcctt atgacagcaa gaactgtgta tgatgatggt 11460
gctaggagag tgtggacact tatgaatgtc ttgacactcg tttataaagt ttattatggt 11520
aatgctttag atcaagccat ttccatgtgg gctcttataa tctctgttac ttctaactac 11580
tcaggtgtag ttacaactgt catgtttttg gccagaggta ttgtttttat gtgtgttgag 11640
tattgcccta ttttcttcat aactggtaat acacttcagt gtataatgct agtttattgt 11700
ttcttaggct atttttgtac ttgttacttt ggcctctttt gtttactcaa ccgctacttt 11760
agactgactc ttggtgttta tgattactta gtttctacac aggagtttag atatatgaat 11820
tcacagggac tactcccacc caagaatagc atagatgcct tcaaactcaa cattaaattg 11880
ttgggtgttg gtggcaaacc ttgtatcaaa gtagccactg tacagtctaa aatgtcagat 11940
gtaaagtgca catcagtagt cttactctca gttttgcaac aactcagagt agaatcatca 12000
tctaaattgt gggctcaatg tgtccagtta cacaatgaca ttctcttagc taaagatact 12060
actgaagcct ttgaaaaaat ggtttcacta ctttctgttt tgctttccat gcagggtgct 12120
gtagacataa acaagctttg tgaagaaatg ctggacaaca gggcaacctt acaagctata 12180
gcctcagagt ttagttccct tccatcatat gcagcttttg ctactgctca agaagcttat 12240
gagcaggctg ttgctaatgg tgattctgaa gttgttctta aaaagttgaa gaagtctttg 12300
aatgtggcta aatctgaatt tgaccgtgat gcagccatgc aacgtaagtt ggaaaagatg 12360
gctgatcaag ctatgaccca aatgtataaa caggctagat ctgaggacaa gagggcaaaa 12420
gttactagtg ctatgcagac aatgcttttc actatgctta gaaagttgga taatgatgca 12480
ctcaacaaca ttatcaacaa tgcaagagat ggttgtgttc ccttgaacat aatacctctt 12540
acaacagcag ccaaactaat ggttgtcata ccagactata acacatataa aaatacgtgt 12600
gatggtacaa catttactta tgcatcagca ttgtgggaaa tccaacaggt tgtagatgca 12660
gatagtaaaa ttgttcaact tagtgaaatt agtatggaca attcacctaa tttagcatgg 12720
cctcttattg taacagcttt aagggccaat tctgctgtca aattacagaa taatgagctt 12780
agtcctgttg cactacgaca gatgtcttgt gctgccggta ctacacaaac tgcttgcact 12840
gatgacaatg cgttagctta ctacaacaca acaaagggag gtaggtttgt acttgcactg 12900
ttatccgatt tacaggattt gaaatgggct agattcccta agagtgatgg aactggtact 12960
atctatacag aactggaacc accttgtagg tttgttatag acacacctaa aggtcctaaa 13020
gtgaagtatt tatactttat taaaggatta aacaacctaa atagaggtat ggtacttggt 13080
agtttagctg ccacagtacg tctacaagct ggtaatgcaa cagaagtgcc tgccaattca 13140
actgtattat ctttctgtgc ttttgctgta gatgctgcta aagcttacaa agattatcta 13200
gctagtgggg gacaaccaat cactaattgt gttaagatgt tgtgtacaca cactggtact 13260
ggtcaggcaa taacagttac accggaagcc aatatggatc aagaatcctt tggtggtgca 13320
tcgtgttgtc tgtactgccg ttgccacata gatcatccaa atcctaaagg attttgtgac 13380
ttaaaaggta agtatgtaca aatacctaca acttgtgcta atgaccctgt gggttttaca 13440
cttaaaaaca cagtctgtac cgtctgcggt atgtggaaag gttatggctg tagttgtgat 13500
caactccgcg aacccatgct tcagtcagct gatgcacaat cgtttttaaa cgggtttgcg 13560
gtgtaagtgc agcccgtctt acaccgtgcg gcacaggcac tagtactgat gtcgtataca 13620
gggcttttga catctacaat gataaagtag ctggttttgc taaattccta aaaactaatt 13680
gttgtcgctt ccaagaaaag gacgaagatg acaatttaat tgattcttac tttgtagtta 13740
agagacacac tttctctaac taccaacatg aagaaacaat ttataattta cttaaggatt 13800
gtccagctgt tgctaaacat gacttcttta agtttagaat agacggtgac atggtaccac 13860
atatatcacg tcaacgtctt actaaataca caatggcaga cctcgtctat gctttaaggc 13920
attttgatga aggtaattgt gacacattaa aagaaatact tgtcacatac aattgttgtg 13980
atgatgatta tttcaataaa aaggactggt atgattttgt agaaaaccca gatatattac 14040
gcgtatacgc caacttaggt gaacgtgtac gccaagcttt gttaaaaaca gtacaattct 14100
gtgatgccat gcgaaatgct ggtattgttg gtgtactgac attagataat caagatctca 14160
atggtaactg gtatgatttc ggtgatttca tacaaaccac gccaggtagt ggagttcctg 14220
ttgtagattc ttattattca ttgttaatgc ctatattaac cttgaccagg gctttaactg 14280
cagagtcaca tgttgacact gacttaacaa agccttacat taagtgggat ttgttaaaat 14340
atgacttcac ggaagagagg ttaaaactct ttgaccgtta ttttaaatat tgggatcaga 14400
cataccaccc aaattgtgtt aactgtttgg atgacagatg cattctgcat tgtgcaaact 14460
ttaatgtttt attctctaca gtgttcccac ctacaagttt tggaccacta gtgagaaaaa 14520
tatttgttga tggtgttcca tttgtagttt caactggata ccacttcaga gagctaggtg 14580
ttgtacataa tcaggatgta aacttacata gctctagact tagttttaag gaattacttg 14640
tgtatgctgc tgaccctgct atgcacgctg cttctggtaa tctattacta gataaacgca 14700
ctacgtgctt ttcagtagct gcacttacta acaatgttgc ttttcaaact gtcaaacccg 14760
gtaattttaa caaagacttc tatgactttg ctgtgtctaa gggtttcttt aaggaaggaa 14820
gttctgttga attaaaacac ttcttctttg ctcaggatgg taatgctgct atcagcgatt 14880
atgactacta tcgttataat ctaccaacaa tgtgtgatat cagacaacta ctatttgtag 14940
ttgaagttgt tgataagtac tttgattgtt acgatggtgg ctgtattaat gctaaccaag 15000
tcatcgtcaa caacctagac aaatcagctg gttttccatt taataaatgg ggtaaggcta 15060
gactttatta tgattcaatg agttatgagg atcaagatgc acttttcgca tatacaaaac 15120
gtaatgtcat ccctactata actcaaatga atcttaagta tgccattagt gcaaagaata 15180
gagctcgcac cgtagctggt gtctctatct gtagtactat gaccaataga cagtttcatc 15240
aaaaattatt gaaatcaata gccgccacta gaggagctac tgtagtaatt ggaacaagca 15300
aattctatgg tggttggcac aacatgttaa aaactgttta tagtgatgta gaaaaccctc 15360
accttatggg ttgggattat cctaaatgtg atagagccat gcctaacatg cttagaatta 15420
tggcctcact tgttcttgct cgcaaacata caacgtgttg tagcttgtca caccgtttct 15480
atagattagc taatgagtgt gctcaagtat tgagtgaaat ggtcatgtgt ggcggttcac 15540
tatatgttaa accaggtgga acctcatcag gagatgccac aactgcttat gctaatagtg 15600
tttttaacat ttgtcaagct gtcacggcca atgttaatgc acttttatct actgatggta 15660
acaaaattgc cgataagtat gtccgcaatt tacaacacag actttatgag tgtctctata 15720
gaaatagaga tgttgacaca gactttgtga atgagtttta cgcatatttg cgtaaacatt 15780
tctcaatgat gatactctct gacgatgctg ttgtgtgttt caatagcact tatgcatctc 15840
aaggtctagt ggctagcata aagaacttta agtcagttct ttattatcaa aacaatgttt 15900
ttatgtctga agcaaaatgt tggactgaga ctgaccttac taaaggacct catgaatttt 15960
gctctcaaca tacaatgcta gttaaacagg gtgatgatta tgtgtacctt ccttacccag 16020
atccatcaag aatcctaggg gccggctgtt ttgtagatga tatcgtaaaa acagatggta 16080
cacttatgat tgaacggttc gtgtctttag ctatagatgc ttacccactt actaaacatc 16140
ctaatcagga gtatgctgat gtctttcatt tgtacttaca atacataaga aagctacatg 16200
atgagttaac aggacacatg ttagacatgt attctgttat gcttactaat gataacactt 16260
caaggtattg ggaacctgag ttttatgagg ctatgtacac accgcataca gtcttacagg 16320
ctgttggggc ttgtgttctt tgcaattcac agacttcatt aagatgtggt gcttgcatac 16380
gtagaccatt cttatgttgt aaatgctgtt acgaccatgt catatcaaca tcacataaat 16440
tagtcttgtc tgttaatccg tatgtttgca atgctccagg ttgtgatgtc acagatgtga 16500
ctcaacttta cttaggaggt atgagctatt attgtaaatc acataaacca cccattagtt 16560
ttccattgtg tgctaatgga caagtttttg gtttatataa aaatacatgt gttggtagcg 16620
ataatgttac tgactttaat gcaattgcaa catgtgactg gacaaatgct ggtgattaca 16680
ttttagctaa cacctgtact gaaagactca agctttttgc agcagaaacg ctcaaagcta 16740
ctgaggagac atttaaactg tcttatggta ttgctactgt acgtgaagtg ctgtctgaca 16800
gagaattaca tctttcatgg gaagttggta aacctagacc accacttaac cgaaattatg 16860
tctttactgg ttatcgtgta actaaaaaca gtaaagtaca aataggagag tacacctttg 16920
aaaaaggtga ctatggtgat gctgttgttt accgaggtac aacaacttac aaattaaatg 16980
ttggtgatta ttttgtgctg acatcacata cagtaatgcc attaagtgca cctacactag 17040
tgccacaaga gcactatgtt agaattactg gcttataccc aacactcaat atctcagatg 17100
agttttctag caatgttgca aattatcaaa aggttggtat gcaaaagtat tctacactcc 17160
agggaccacc tggtactggt aagagtcatt ttgctattgg cctagctctc tactaccctt 17220
ctgctcgcat agtgtataca gcttgctctc atgccgctgt tgatgcacta tgtgagaagg 17280
cattaaaata tttgcctata gataaatgta gtagaattat acctgcacgt gctcgtgtag 17340
agtgttttga taaattcaaa gtgaattcaa cattagaaca gtatgtcttt tgtactgtaa 17400
atgcattgcc tgagacgaca gcagatatag ttgtctttga tgaaatttca atggccacaa 17460
attatgattt gagtgttgtc aatgccagat tacgtgctaa gcactatgtg tacattggcg 17520
accctgctca attacctgca ccacgcacat tgctaactaa gggcacacta gaaccagaat 17580
atttcaattc agtgtgtaga cttatgaaaa ctataggtcc agacatgttc ctcggaactt 17640
gtcggcgttg tcctgctgaa attgttgaca ctgtgagtgc tttggtttat gataataagc 17700
ttaaagcaca taaagacaaa tcagctcaat gctttaaaat gttttataag ggtgttatca 17760
cgcatgatgt ttcatctgca attaacaggc cacaaatagg cgtggtaaga gaattcctta 17820
cacgtaaccc tgcttggaga aaagctgtct ttatttcacc ttataattca cagaatgctg 17880
tagcctcaaa gattttggga ctaccaactc aaactgttga ttcatcacag ggctcagaat 17940
atgactatgt catattcact caaaccactg aaacagctca ctcttgtaat gtaaacagat 18000
ttaatgttgc tattaccaga gcaaaagtag gcatactttg cataatgtct gatagagacc 18060
tttatgacaa gttgcaattt acaagtcttg aaattccacg taggaatgtg gcaactttac 18120
aagctgaaaa tgtaacagga ctctttaaag attgtagtaa ggtaatcact gggttacatc 18180
ctacacaggc acctacacac ctcagtgttg acactaaatt caaaactgaa ggtttatgtg 18240
ttgacatacc tggcatacct aaggacatga cctatagaag actcatctct atgatgggtt 18300
ttaaaatgaa ttatcaagtt aatggttacc ctaacatgtt tatcacccgc gaagaagcta 18360
taagacatgt acgtgcatgg attggcttcg atgtcgaggg gtgtcatgct actagagaag 18420
ctgttggtac caatttacct ttacagctag gtttttctac aggtgttaac ctagttgctg 18480
tacctacagg ttatgttgat acacctaata atacagattt ttccagagtt agtgctaaac 18540
caccgcctgg agatcaattt aaacacctca taccacttat gtacaaagga cttccttgga 18600
atgtagtgcg tataaagatt gtacaaatgt taagtgacac acttaaaaat ctctctgaca 18660
gagtcgtatt tgtcttatgg gcacatggct ttgagttgac atctatgaag tattttgtga 18720
aaataggacc tgagcgcacc tgttgtctat gtgatagacg tgccacatgc ttttccactg 18780
cttcagacac ttatgcctgt tggcatcatt ctattggatt tgattacgtc tataatccgt 18840
ttatgattga tgttcaacaa tggggtttta caggtaacct acaaagcaac catgatctgt 18900
attgtcaagt ccatggtaat gcacatgtag ctagttgtga tgcaatcatg actaggtgtc 18960
tagctgtcca cgagtgcttt gttaagcgtg ttgactggac tattgaatat cctataattg 19020
gtgatgaact gaagattaat gcggcttgta gaaaggttca acacatggtt gttaaagctg 19080
cattattagc agacaaattc ccagttcttc acgacattgg taaccctaaa gctattaagt 19140
gtgtacctca agctgatgta gaatggaagt tctatgatgc acatccttgt agtgacaaag 19200
cttataaaat agaagaatta ttctattctt atgccacaca ttctgacaaa ttcacagatg 19260
gtgtatgcct attttggaat tgcaatgtcg atagatatcc tgctaattcc attgtttgta 19320
gatttgacac tagagtgcta tctaacctta acttgcctgg ttgtgatggt ggcagtttgt 19380
atgtaaataa acatgcattc cacacaccag cttttgataa aagtgctttt gttaatttaa 19440
aacaattacc atttttctat tactctgaca gtccatgtga gtctcatgga aaacaagtag 19500
tgtcagatat agattatgta ccactaaagt ctgctacgtg tataacacgt tgcaatttag 19560
gtggtgctgt ctgtagacat catgctaatg agtacagatt gtatctcgat gcttataaca 19620
tgatgatctc agctggcttt agcttgtggg tttacaaaca atttgatact tataacctct 19680
ggaacacttt tacaagactt cagagtttag aaaatgtggc ttttaatgtt gtaaataagg 19740
gacactttga tggacaacag ggtgaagtac cagtttctat cattaataac actgtttaca 19800
caaaagttga tggtgttgat gtagaattgt ttgaaaataa aacaacatta cctgttaatg 19860
tagcatttga gctttgggct aagcgcaaca ttaaaccagt accagaggtg aaaatactca 19920
ataatttggg tgtggacatt gctgctaata ctgtgatctg ggactacaaa agagatgctc 19980
cagcacatat atctactatt ggtgtttgtt ctatgactga catagccaag aaaccaactg 20040
aaacgatttg tgcaccactc actgtctttt ttgatggtag agttgatggt caagtagact 20100
tatttagaaa tgcccgtaat ggtgttctta ttacagaagg tagtgttaaa ggtttacaac 20160
catctgtagg tcccaaacaa gctagtctta atggagtcac attaattgga gaagccgtaa 20220
aaacacagtt caattattat aagaaagttg atggtgttgt ccaacaatta cctgaaactt 20280
actttactca gagtagaaat ttacaagaat ttaaacccag gagtcaaatg gaaattgatt 20340
tcttagaatt agctatggat gaattcattg aacggtataa attagaaggc tatgccttcg 20400
aacatatcgt ttatggagat tttagtcata gtcagttagg tggtttacat ctactgattg 20460
gactagctaa acgttttaag gaatcacctt ttgaattaga agattttatt cctatggaca 20520
gtacagttaa aaactatttc ataacagatg cgcaaacagg ttcatctaag tgtgtgtgtt 20580
ctgttattga tttattactt gatgattttg ttgaaataat aaaatcccaa gatttatctg 20640
tagtttctaa ggttgtcaaa gtgactattg actatacaga aatttcattt atgctttggt 20700
gtaaagatgg ccatgtagaa acattttacc caaaattaca atctagtcaa gcgtggcaac 20760
cgggtgttgc tatgcctaat ctttacaaaa tgcaaagaat gctattagaa aagtgtgacc 20820
ttcaaaatta tggtgatagt gcaacattac ctaaaggcat aatgatgaat gtcgcaaaat 20880
atactcaact gtgtcaatat ttaaacacat taacattagc tgtaccctat aatatgagag 20940
ttatacattt tggtgctggt tctgataaag gagttgcacc aggtacagct gttttaagac 21000
agtggttgcc tacgggtacg ctgcttgtcg attcagatct taatgacttt gtctctgatg 21060
cagattcaac tttgattggt gattgtgcaa ctgtacatac agctaataaa tgggatctca 21120
ttattagtga tatgtacgac cctaagacta aaaatgttac aaaagaaaat gactctaaag 21180
agggtttttt cacttacatt tgtgggttta tacaacaaaa gctagctctt ggaggttccg 21240
tggctataaa gataacagaa cattcttgga atgctgatct ttataagctc atgggacact 21300
tcgcatggtg gacagccttt gttactaatg tgaatgcgtc atcatctgaa gcatttttaa 21360
ttggatgtaa ttatcttggc aaaccacgcg aacaaataga tggttatgtc atgcatgcaa 21420
attacatatt ttggaggaat acaaatccaa ttcagttgtc ttcctattct ttatttgaca 21480
tgagtaaatt tccccttaaa ttaaggggta ctgctgttat gtctttaaaa gaaggtcaaa 21540
tcaatgatat gattttatct cttcttagta aaggtagact tataattaga gaaaacaaca 21600
gagttgttat ttctagtgat gttcttgtta acaactaaac gaacaatgtt tgtttttctt 21660
gttttattgc cactagtctc tagtcagtgt gttaatctta caaccagaac tcaattaccc 21720
cctgcataca ctaattcttt cacacgtggt gtttattacc ctgacaaagt tttcagatcc 21780
tcagttttac attcaactca ggacttgttc ttacctttct tttctaatgt tacttggttc 21840
catgctatac atgtctctgg gaccaaaggt actaagaggt ttgataaccc tgtcctacca 21900
tttaatgatg gtgtttattt tgcttccact gagaagtcta acataataag aggctggatt 21960
tttggtacta ctttagattc gaagacccag tccctactta ttgttaataa cgctactaat 22020
gttgttatta aagtctgtga atttcaattt tgtaatgatc catttttggg tgtttattac 22080
cacaaaaaca acaaaagttg gatggaaagt gagttcagag tttattctag tgcgaataat 22140
tgcacttttg aatatgtctc tcagcctttt cttatggacc ttgaaggaaa acagggtaat 22200
ttcaaaaatc ttagggaatt tgtgtttaag aatattgatg gttattttaa aatatattct 22260
aagcacacgc ctattaattt agtgcgtgat ctccctcagg gtttttcggc tttagaacca 22320
ttggtagatt tgccaatagg tattaacatc actaggtttc aaactttact tgctttacat 22380
agaagttatt tgactcctgg tgattcttct tcaggttgga cagctggtgc tgcagcttat 22440
tatgtgggtt atcttcaacc taggactttt ctattaaaat ataatgaaaa tggaaccatt 22500
acagatgctg tagactgtgc acttgaccct ctctcagaaa caaagtgtac gttgaaatcc 22560
ttcactgtag aaaaaggaat ctatcaaact tctaacttta gagtccaacc aacagaatct 22620
attgttagat ttcctaatat tacaaacttg tgcccttttg gtgaagtttt taacgccacc 22680
agatttgcat ctgtttatgc ttggaacagg aagagaatca gcaactgtgt tgctgattat 22740
tctgtcctat ataattccgc atcattttcc acttttaagt gttatggagt gtctcctact 22800
aaattaaatg atctctgctt tactaatgtc tatgcagatt catttgtaat tagaggtgat 22860
gaagtcagac aaatcgctcc agggcaaact ggaaagattg ctgattataa ttataaatta 22920
ccagatgatt ttacaggctg cgttatagct tggaattcta acaatcttga ttctaaggtt 22980
ggtggtaatt ataattacct gtatagattg tttaggaagt ctaatctcaa accttttgag 23040
agagatattt caactgaaat ctatcaggcc ggtagcacac cttgtaatgg tgttgaaggt 23100
tttaattgtt actttccttt aaaatcatat ggtttccacc ccactaatgg tgttggttac 23160
caaccataca gagtagtagt actttctttt gaacttctac atgcaccagc aactgtttgt 23220
ggacctaaaa agtctactaa tttggttaaa aacaaatgtg tcaatttcaa cttcaatggt 23280
ttaacaggca caggtgttct tactgagtct aacaaaaagt ttctgccttt ccaacaattt 23340
ggcagagaca ttgctgacac tactgatgct gtccgtgatc cacagacact tgagattctt 23400
gacattacac catgttcttt tggtggtgtc agtgttataa caccaggaac aaatacttct 23460
aaccaggttg ctgttcttta tcaggatgtt aactgcacag aagtccctgt tgctattcat 23520
gcagatcaac ttactcctac ttggcgtgtt tattctacag gttctaatgt ttttcaaaca 23580
cgtgcaggct gtttaatagg ggctgaatat gtcaacaact catatgagtg tgacataccc 23640
attggtgcag gtatatgcgc tagttatcag actcagacta attctcctcg gcgggcacgt 23700
agtgtagcta gtcaatccat cattgcctac actatgtcac ttggtgcaga aaattcagtt 23760
gcttactcta ataactctat tgccataccc acaaatttta ctattagtgt taccacagaa 23820
attctaccag tgtctatgac caagacatca gtagattgta caatgtacat ttgtggtgat 23880
tcaactgaat gcagcaatct tttgttgcaa tatggcagtt tttgtacaca attaaaccgt 23940
gctttaactg gaatagctgt tgaacaagac aaaaacaccc aagaagtttt tgcacaagtc 24000
aaacaaattt acaaaacacc accaattaaa gattttggtg gttttaattt ttcacaaata 24060
ttaccagatc catcaaaacc aagcaagagg tcatttattg aagatctact tttcaacaaa 24120
gtgacacttg cagatgctgg cttcatcaaa caatatggtg attgccttgg tgatattgct 24180
gctagagacc tcatttgtgc acaaaagttt aacggcctta ctgttttgcc acctttgctc 24240
acagatgaaa tgattgctca atacacttct gcactgttag cgggtacaat cacttctggt 24300
tggacctttg gtgcaggtgc tgcattacaa ataccatttg ctatgcaaat ggcttatagg 24360
tttaatggta ttggagttac acagaatgtt ctctatgaga accaaaaatt gattgccaac 24420
caatttaata gtgctattgg caaaattcaa gactcacttt cttccacagc aagtgcactt 24480
ggaaaacttc aagatgtggt caaccaaaat gcacaagctt taaacacgct tgttaaacaa 24540
cttagctcca attttggtgc aatttcaagt gttttaaatg atatcctttc acgtcttgac 24600
aaagttgagg ctgaagtgca aattgatagg ttgatcacag gcagacttca aagtttgcag 24660
acatatgtga ctcaacaatt aattagagct gcagaaatca gagcttctgc taatcttgct 24720
gctactaaaa tgtcagagtg tgtacttgga caatcaaaaa gagttgattt ttgtggaaag 24780
ggctatcatc ttatgtcctt ccctcagtca gcacctcatg gtgtagtctt cttgcatgtg 24840
acttatgtcc ctgcacaaga aaagaacttc acaactgctc ctgccatttg tcatgatgga 24900
aaagcacact ttcctcgtga aggtgtcttt gtttcaaatg gcacacactg gtttgtaaca 24960
caaaggaatt tttatgaacc acaaatcatt actacagaca acacatttgt gtctggtaac 25020
tgtgatgttg taataggaat tgtcaacaac acagtttatg atcctttgca acctgaatta 25080
gactcattca aggaggagtt agataaatat tttaagaatc atacatcacc agatgttgat 25140
ttaggtgaca tctctggcat taatgcttca gttgtaaaca ttcaaaaaga aattgaccgc 25200
ctcaatgagg ttgccaagaa tttaaatgaa tctctcatcg atctccaaga acttggaaag 25260
tatgagcagt atataaaatg gccatggtac atttggctag gttttatagc tggcttgatt 25320
gccatagtaa tggtgacaat tatgctttgc tgtatgacca gttgctgtag ttgtctcaag 25380
ggctgttgtt cttgtggatc ctgctgcaaa tttgatgaag acgactctga gccagtgctc 25440
aaaggagtca aattacatta cacataaacg aacttatgga tttgtttatg agaatcttca 25500
caattggaac tgtaactttg aagcaaggtg aaatcaagga tgctactcct tcagattttg 25560
ttcgcgctac tgcaacgata ccgatacaag cctcactccc tttcggatgg cttattgttg 25620
gcgttgcact tcttgctgtt tttcagagcg cttccaaaat cataaccctc aaaaagagat 25680
ggcaactagc actctccaag ggtgttcact ttgtttgcaa cttgctgttg ttgtttgtaa 25740
cagtttactc acaccttttg ctcgttgctg ctggccttga agcccctttt ctctatcttt 25800
atgctttagt ctacttcttg cagagtataa actttgtaag aataataatg aggctttggc 25860
tttgctggaa atgccgttcc aaaaacccat tactttatga tgccaactat tttctttgct 25920
ggcatactaa ttgttacgac tattgtatac cttacaatag tgtaacttct tcaattgtca 25980
ttacttcagg tgatggcaca acaagtccta tttctgaaca tgactaccag attggtggtt 26040
atactgaaaa atgggaatct ggagtaaaag actgtgttgt attacacagt tacttcactt 26100
cagactatta ccagctgtac tcaactcaat tgagtacaga cactggtgtt gaacatgtta 26160
ccttcttcat ctacaataaa attgttgatg agcctgaaga acatgtccaa attcacacaa 26220
tcgacggttc atccggagtt gttaatccag taatggaacc aatttatgat gaaccgacga 26280
cgactactag cgtgcctttg taagcacaag ctgatgagta cgaacttatg tactcattcg 26340
tttcggaaga gacaggtacg ttaatagtta atagcgtact tctttttctt gctttcgtgg 26400
tattcttgct agttacacta gccatcctta ctgcgcttcg attgtgtgcg tactgctgca 26460
atattgttaa cgtgagtctt gtaaaacctt ctttttacgt ttactctcgt gttaaaaatc 26520
tgaattcttc tagagttcct gatcttctgg tctaaacgaa ctaaatatta tattagtttt 26580
tctgtttgga actttaattt tagccatggc agattccaac ggtactatta ccgttgaaga 26640
gcttaaaaag ctccttgaac aatggaacct agtaataggt ttcctattcc ttacatggat 26700
ttgtcttcta caatttgcct atgccaacag gaataggttt ttgtatataa ttaagttaat 26760
tttcctctgg ctgttatggc cagtaacttt agcttgtttt gtgcttgctg ctgtttacag 26820
aataaattgg atcaccggtg gaattgctat cgcaatggct tgtcttgtag gcttgatgtg 26880
gctcagctac ttcattgctt ctttcagact gtttgcgcgt acgcgttcca tgtggtcatt 26940
caatccagaa actaacattc ttctcaacgt gccactccat ggcactattc tgaccagacc 27000
gcttctagaa agtgaactcg taatcggagc tgtgatcctt cgtggacatc ttcgtattgc 27060
tggacaccat ctaggacgct gtgacatcaa ggacctgcct aaagaaatca ctgttgctac 27120
atcacgaacg ctttcttatt acaaattggg agcttcgcag cgtgtagcag gtgactcagg 27180
ttttgctgca tacagtcgct acaggattgg caactataaa ttaaacacag accattccag 27240
tagcagtgac aatattgctt tgcttgtaca gtaagtgaca acagatgttt catctcgttg 27300
actttcaggt tactatagca gagatattac taattattat gaggactttt aaagtttcca 27360
tttggaatct tgattacatc ataaacctca taattaaaaa tttatctatt gaattgtgcg 27420
tggatgaggc tggttctaaa tcacccattc agtacatcga tatcggtaat tatacagttt 27480
cctgtttacc ttttacaatt aattgccagg aacctaaatt gggtagtctt gtagtgcgtt 27540
gttcgttcta tgaagacttt ttagagtatc atgacgttcg tgttgtttta gatttcatct 27600
aaacgaacaa actaaaatgt ctgataatgg accccaaaat cagcgaaatg caccccgcat 27660
tacgtttggt ggaccctcag attcaactgg cagtaaccag aatggagaac gcagtggggc 27720
gcgatcaaaa caacgtcggc cccaaggttt acccaataat actgcgtctt ggttcaccgc 27780
tctcactcaa catggcaagg aagaccttaa attccctcga ggacaaggcg ttccaattaa 27840
caccaatagc agtccagatg accaaattgg ctactaccga agagctacca gacgaattcg 27900
tggtggtgac ggtaaaatga aagatctcag tccaagatgg tatttctact acctaggaac 27960
tgggccagaa gctggacttc cctatggtgc taacaaagac ggcatcatat gggttgcaac 28020
tgagggagcc ttgaatacac caaaagatca cattggcacc cgcaatcctg ctaacaatgc 28080
tgcaatcgtg ctacaacttc ctcaaggaac aacattgcca aaaggcttct acgcagaagg 28140
gagcagaggc ggcagtcaag cctcttctcg ttcctcatca cgtagtcgca acagttcaag 28200
aaattcaact ccaggcagca gtaggggaac ttctcctgct agaatggctg gcaatggcgg 28260
tgatgctgct cttgctttgc tgctgcttga cagattgaac cagctcgaga gcaaaatgtc 28320
tggtaaaggc caacaacaac aaggccaaac tgtcactaag aaatctgctg ctgaggcttc 28380
taagaagcct cggcaaaaac gtactgccac taaagcatac aatgtaacac aagctttcgg 28440
cagacgtggt ccagaacaaa cccaaggaaa ttttggggac caggaactaa tcagacaagg 28500
aactgattac aaacattggc cgcaaattgc acaatttgcc cccagcgctt cagcgttctt 28560
cggaatgtcg cgcattggca tggaagtcac accttcggga acgtggttga cctacacagg 28620
tgccatcaaa ttggatgaca aagatccaaa tttcaaagat caagtcattt tgctgaataa 28680
gcatattgac gcatacaaaa cattcccacc aacagagcct aaaaaggaca aaaagaagaa 28740
ggctgatgaa actcaagcct taccgcagag acagaagaaa cagcaaactg tgactcttct 28800
tcctgctgca gatttggatg atttctccaa acaattgcaa caatccatga gcagtgctga 28860
ctcaactcag gcctaaactc atgcagacca cacaaggcag atgggctata taaacatttt 28920
cgcttttccg tttacgatat atagtctact cttgtgcaga atgaattctc gtaactacat 28980
agcacaagta gatgtagtta actttaatct cacatagcaa tctttaatca gtgtgtaaca 29040
ttagggagga cttgaaagag ccaccacatt ttcaccgagg ccacgcggag tacgatcgag 29100
tgtacagtga acaatgctag ggagagctgc ctatatggaa gagccctaat gtgtaaaatt 29160
aattttagta gtgctatccc catgtgattt taatagcttc ttaggagaat gacaaaaa 29218
<210> 2
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
ccagatgatt ttacaggctg cgtta 25
<210> 3
<211> 28
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
tgtcaagaat ctcaagtgtc tgtggatc 28
<210> 4
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
atgagggtcc aaccaacaga gagc 24
<210> 5
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
Claims (8)
1. An isolated novel coronavirus having the accession number: CCTCC NO: V202107.
2. Use of the virus of claim 1 for the preparation of milk or serum containing positive antibodies to novel coronaviruses.
3. The use of claim 2, wherein the novel coronavirus is prepared into an immunizing agent and then used for immunizing a cow, and the novel coronavirus is obtained by centrifuging a novel coronavirus liquid which is qualified in inactivation verification to remove cell debris, and then concentrating the solution to obtain an antigen with high concentration;
preparation of an aqueous phase: adding 2% -4% of Tween 80 into the concentrated antigen;
preparing an oil phase: adding 5-6% span 85 and 1-2% aluminum stearate into macroro 152 white oil, and sterilizing
And mixing the water phase and the oil phase according to the proportion of 3: 2-4: 3 to obtain the new coronavirus immune preparation.
4. The use of claim 2, wherein the prepared milk or serum is used to evaluate a novel coronavirus animal model, wherein the model is constructed by infecting a mouse with SARS-CoV-2/WBP-1, wherein the SARS-CoV-2/WBP-1 has a collection number of CCTCC NO: v202031.
5. Use of milk prepared by the use of claim 2 in the preparation of a drinkable medicament for neutralizing novel coronaviruses.
6. Use of milk or serum prepared by the use according to claim 2 in the manufacture of a medicament for the treatment or prevention of a novel coronavirus infection.
7. Use of milk or serum prepared by the use as claimed in claim 2 for the preparation of novel antibodies to coronavirus Igs.
8. The use according to claim 7 of said Igs antibodies for the preparation of a medicament for the treatment or prevention of a novel coronavirus infection.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010881428.7A CN111961132A (en) | 2020-08-27 | 2020-08-27 | Preparation method and application of specific antibody-containing milk or serum produced by novel coronavirus immune dairy cows |
CN2020108814287 | 2020-08-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113429477A CN113429477A (en) | 2021-09-24 |
CN113429477B true CN113429477B (en) | 2022-06-07 |
Family
ID=73401158
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010881428.7A Pending CN111961132A (en) | 2020-08-27 | 2020-08-27 | Preparation method and application of specific antibody-containing milk or serum produced by novel coronavirus immune dairy cows |
CN202110011295.2A Active CN113429477B (en) | 2020-08-27 | 2021-01-06 | Preparation method and application of novel coronavirus, milk or serum containing specific antibody and produced by immune dairy cow thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010881428.7A Pending CN111961132A (en) | 2020-08-27 | 2020-08-27 | Preparation method and application of specific antibody-containing milk or serum produced by novel coronavirus immune dairy cows |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN111961132A (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112806435A (en) * | 2020-12-28 | 2021-05-18 | 青岛今墨堂生物技术有限公司 | Preparation method of milk containing anti-new coronavirus antibody |
WO2022241057A1 (en) * | 2021-05-12 | 2022-11-17 | Applied Biomedical Science Institute | Binding polypeptides against sars cov-2 and uses thereof |
CN113583970B (en) * | 2021-07-29 | 2023-05-12 | 吉林大学 | A medicine for preventing or resisting coronavirus transmission and pathopoiesia, and its preparation method |
CN114774412A (en) * | 2022-03-15 | 2022-07-22 | 上海市东方医院(同济大学附属东方医院) | New coronavirus vmiRNA precursor sequence, new coronavirus vmiRNA and application |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1063091C (en) * | 1997-09-01 | 2001-03-14 | 黄河 | Functional milk for immunization |
JP2002191287A (en) * | 2000-12-26 | 2002-07-09 | Ogawa & Co Ltd | Method for disinfecting milk containing antibody and food, etc., containing disinfected antibody-containing milk |
CN1502367A (en) * | 2003-05-15 | 2004-06-09 | 广州呼吸疾病研究所 | Immunoprophyaxis nose drops and preparation process thereof |
CN100379349C (en) * | 2004-03-10 | 2008-04-09 | 王庭桂 | Method for preparing immune milk anti-pathogenic microoganism in digestive tract |
CN101040632B (en) * | 2006-03-23 | 2013-01-30 | 深圳雅臣生物科技有限公司 | Milk product with specific immunity of anti-enterobacter sakazakii and the preparing method thereof |
CN102397556A (en) * | 2011-05-23 | 2012-04-04 | 上海创宏生物科技有限公司 | Heatproof protection agent for live vaccine of duck viral hepatitis (DVH), preparation method thereof and application thereof |
CN103592436A (en) * | 2012-08-15 | 2014-02-19 | 华中农业大学 | A-type H1 subtype influenza virus antibody blocking ELISA kit and applications thereof |
CN103468647B (en) * | 2013-09-03 | 2015-04-22 | 华中农业大学 | Swine flu H1N1 and H3N2 subtype bivalent inactivated vaccine |
CN110184242B (en) * | 2019-06-11 | 2021-08-20 | 武汉生物制品研究所有限责任公司 | Mouse virulent challenge strain of Coxsackie virus group A6 (CVA6) and application thereof |
CN111471103A (en) * | 2020-03-20 | 2020-07-31 | 唐山怡安生物工程有限公司 | Heterologous antibody of new coronavirus (2019-nCOV) and preparation method thereof |
WO2020143892A2 (en) * | 2020-04-28 | 2020-07-16 | Lachlak Nassira | Probiotic which cures covid 19 patients by transfer of natural passive immunity from immunised cows |
-
2020
- 2020-08-27 CN CN202010881428.7A patent/CN111961132A/en active Pending
-
2021
- 2021-01-06 CN CN202110011295.2A patent/CN113429477B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN111961132A (en) | 2020-11-20 |
CN113429477A (en) | 2021-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113429477B (en) | Preparation method and application of novel coronavirus, milk or serum containing specific antibody and produced by immune dairy cow thereof | |
CN113583972B (en) | Escherichia coli bacteriophage capable of reducing antibiotic resistance and application thereof | |
CN107287218B (en) | Avian infectious bronchitis virulent strain S1 gene and virulent strain and application thereof | |
CN113337478B (en) | Cat parvovirus strain and application thereof | |
CN104099301B (en) | Coxsackie virus A16 type virus strain, application, vaccine and preparation method thereof | |
He et al. | Prokaryotic expression and purification of grass carp reovirus capsid protein VP7 and its vaccine potential | |
CN111961653B (en) | Novel coronavirus mouse adaptive strain SARS-CoV-2/WBP-1 and application thereof | |
CN112921005A (en) | Hybridoma cell strain, canine parvovirus VP2 protein monoclonal antibody generated by hybridoma cell strain and application of monoclonal antibody | |
WO2018000708A1 (en) | Muscovy duck parvovirus subunit vaccine | |
CN114561366B (en) | Goat kuraria virus isolate and application thereof | |
CN113493775A (en) | Porcine delta coronavirus strain and application thereof | |
CN113943714A (en) | Cat calicivirus strain and application thereof | |
CN109957009B (en) | Anti-human 7-type adenovirus antibody 2-1H and application thereof | |
CN109897104B (en) | Human adenovirus 7 monoclonal antibody 3-3E and application thereof | |
CN114524862B (en) | Construction and application of avian influenza (H5 + H7) trivalent DNA vaccine | |
CN106854647B (en) | Duck viral hepatitis bivalent yolk antibody and preparation method and application thereof | |
CN111073863B (en) | Porcine epidemic diarrhea and porcine delta coronavirus bivalent attenuated vaccine and preparation method thereof | |
CN109735504B (en) | Canine distemper virus attenuated vaccine strain and application thereof | |
CN116003537B (en) | Rhabdovirus recombinant G protein, recombinant cell comprising rhabdovirus recombinant G protein and application of rhabdovirus recombinant G protein | |
EP2899267A1 (en) | In vitro preparation method of rotavirus double-layer virus-like particles | |
CN116121202B (en) | Coxsackie virus B group 1 strain and application thereof | |
CN115322971A (en) | Fish circovirus and application thereof | |
CN109593136B (en) | Avian paramyxovirus fusion protein, preparation method and application thereof, and APMV vaccine for pigeons | |
CN109517044B (en) | Porcine epidemic diarrhea virus genetic engineering antigen and antibody | |
CN107158370A (en) | Racoon dog canine distemper freeze-dried live vaccine and its preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |